CClinicalTrials.gg
Not yet recruitingNCT07671300SVTestUpdated Jul 10, 2026

Superficial Vein Thrombosis Testing in the Emergency Department

An observational study in Superficial Vein Thrombosis and D-dimer, sponsored by Dr. Kerstin de Wit. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Dr. Kerstin de Wit · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

Superficial vein thrombosis (SVT) occurs when blood in a vein directly under the skin clots. SVT causes vein tenderness, pain, and skin discolouration. Over time, the vein hardens into a firm, nontender, easily palpable lump. SVT commonly occurs in the veins of the leg. Each year, 1 per 1000 people over the age of 18 have SVT. SVT is painful but usually gets better within a month. Four in 100 people with SVT develop progressively worse blood clotting involving the deep veins or lungs.

If a deep vein clot in the leg occurs it can cause permanent disability with post-thrombotic syndrome (long-term leg pain and swelling) and reduced quality of life. If a pulmonary embolism occurs it may cause chest pain, breathlessness, pulmonary hypertension, psychological distress, and potentially death. Guidelines tell doctors to use ultrasound scanning to decide whether SVT needs treatment with a blood thinner or not. Blood thinners prevent the clot from worsening.

Many people who have SVT go to the emergency department. Scanning is limited to the daytime so often people have multiple trips to the emergency department for their scan and they spend many hours waiting for a doctor to see them. Our research group developed simple ways to limit the need for scans for other types of blood clots, like blood clots in the lungs or in the deep veins. We use a simple blood test called D-dimer. We believe we may be able to use D-dimer to help limit the need for SVT scanning.

This is an exploratory study to document what happens to patients tested for SVT in the emergency department, and to see if the D-dimer blood test might be useful in reducing scans. Our research group will review the emergency department charts for patients who came to the emergency department with SVT. Our results will tell us whether further studies would be helpful.

02

Conditions studied

  • Superficial Vein Thrombosis
  • D-dimer

Browse trials for

Keywords

  • D-dimer
  • Superficial vein thrombosis
  • Emergency Medicine
  • diagnostic
03

In context

Disease

1,327 studies on the registry are indexed under Disease; 596 are open to participants now.

This study's planned enrollment of 400 is above the median of 210 across 573 observational studies indexed under Disease.

Browse Disease studies →

Lead sponsor

Dr. Kerstin de Wit is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Emergency department patient who is tested for superficial vein thrombosis

Inclusion criteria

  • Aged ≥ 18
  • Tested for superficial vein thrombosis in the emergency department or urgent care centre
  • Patients tested for SVT at all sites, including arms, legs and torso

Exclusion criteria

Exclusion Criteria:

  • Patient opted out of research at the participating site
  • Patient included in the study in the last 90 days
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Emergency department patients tested for superficial vein thrombosis

    Diagnostic Test: D-dimer

Interventions

  • Diagnostic testD-dimer

    D-dimer blood test levels will be extracted from medical records. This is an non-interventional study.

06

What researchers measure

Primary outcomes

  1. Superficial vein thrombosis, deep vein thrombosis and no thrombosis

    SVT will be classified as a) situated within 3 cm of the deep vein junction, b) ≥ 5 cm in length and \> 3 cm from the deep vein junction, and c) SVT \< 5 cm in length and \> 3 cm from the deep vein junction. Diagnosis of deep vein thrombosis and the finding of no thrombosis will be reported.

    Time frame: During index testing

Secondary outcomes

  1. The secondary outcomes will the subsequent development of recurrent SVT, SVT propagation, deep vein thrombosis, pulmonary embolism, or death from pulmonary embolism among patients diagnosed with SVT at the index visit.

    Time frame: 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07671300
Lead sponsor
Dr. Kerstin de Wit
Responsible party
Dr. Kerstin de Wit (Professor, Queen's University) — Sponsor-investigator
First posted
Jun 26, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Jul 10, 2026

Study contacts

Natasha S Clayton
Contact
natasha.clayton@queensu.ca
416-566-3590
de Wit, MD
Contact
Kerstin de Wit, MD
principal investigator · Kingston Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion